Brokerages forecast that Krystal Biotech Inc (NASDAQ:KRYS) will report ($0.34) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Krystal Biotech’s earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.29). Krystal Biotech reported earnings of ($0.21) per share during the same quarter last year, which would suggest a negative year over year growth rate of 61.9%. The firm is expected to issue its next quarterly earnings report on Monday, May 6th.
According to Zacks, analysts expect that Krystal Biotech will report full-year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.69) to ($1.18). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.78) per share, with EPS estimates ranging from ($2.10) to ($1.46). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Krystal Biotech.
A number of equities analysts have issued reports on the company. Zacks Investment Research lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Thursday, February 21st. Chardan Capital upped their target price on Krystal Biotech from $50.00 to $57.50 and gave the company a “buy” rating in a research report on Tuesday, March 12th. Finally, ValuEngine raised Krystal Biotech from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $36.90.
Shares of KRYS traded up $1.24 during trading on Friday, reaching $21.10. The company’s stock had a trading volume of 115,666 shares, compared to its average volume of 54,101. Krystal Biotech has a twelve month low of $8.91 and a twelve month high of $28.75. The firm has a market cap of $304.49 million, a price-to-earnings ratio of -21.75 and a beta of 0.55.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Story: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.